In the world of finance and investments, Initial Public Offerings (IPOs) are significant events that mark the transition of a private company into a publicly-traded entity. During an IPO, a company offers its shares to the public for the first time. It allows the company to raise capital by selling ownership stakes to investors. This article delves into the IPO process, focusing on Concord Biotech IPO as an example.
Concord Biotech IPO: An Overview
Concord Biotech, a leading biotechnology company, recently decided to go public, aiming to raise funds for expanding its research and development efforts. The company specializes in the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates for the pharmaceutical industry. With a focus on providing high-quality products, Concord Biotech has gained recognition and trust in the market.
| Concord Biotech IPO Details | |
| IPO Date | Aug 4, 2023 to Aug 8, 2023 |
| Listing Date | [.] |
| Face Value | ₹1 per share |
| Price | [.] to [.] per share |
| Lot Size | – |
| Total Issue Size | 20,925,652 shares |
| (aggregating up to ₹[.] Cr) | |
| Offer for Sale | 20,925,652 shares of ₹1 |
| (aggregating up to ₹[.] Cr) | |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
The decision to go public can be a crucial milestone for a company. It opens doors to opportunities for expansion, growth, and increased market visibility. Concord Biotech’s IPO is no exception.
Reviewing Concord Biotech’s Prospects
Before investing in an IPO, potential investors must examine the company’s prospects thoroughly. Concord Biotech boasts an impressive product portfolio, encompassing various APIs and intermediates used in essential medications. Their commitment to innovation and research sets them apart in the competitive pharmaceutical landscape.
Analyzing a company’s financial performance is equally important. Concord Biotech’s financial reports exhibit steady growth, indicating strong financial health. Additionally, their strategic partnerships and global presence contribute to their favorable market position.
| Company Financials | |||
| Concord Biotech IPO Financial Information (Restated Consolidated) | |||
| Period Ended | 44286 | 44651 | 45016 |
| Assets | 1182.55 | 1312.8 | 1513.98 |
| Revenue | 630.75 | 736.35 | 888.48 |
| Profit After Tax | 234.89 | 174.93 | 240.08 |
| Net Worth | 999.37 | 1103.22 | 1290 |
| Reserves and Surplus | |||
| Total Borrowing | 86.35 | 60.59 | 31.24 |
Analyzing the IPO Price and Allotment
Determining the IPO price is a critical aspect of the offering process. Concord Biotech’s IPO was priced competitively, considering factors such as the company’s valuation, market conditions, and investor demand. A well-calibrated IPO price can attract potential investors and ensure a successful offering.
| Concord Biotech IPO Timetable (Tentative) | |
| Concord Biotech IPO opens on Aug 4, 2023, and closes on Aug 8, 2023. | |
| IPO Open Date | Friday, 4 August 2023 |
| IPO Close Date | Tuesday, 8 August 2023 |
| Basis of Allotment | Friday, 11 August 2023 |
| Initiation of Refunds | Monday, 14 August 2023 |
| Credit of Shares to Demat | Wednesday, 16 August 2023 |
| Listing Date | Thursday, 17 August 2023 |
| Cut-off time for UPI mandate confirmation | 5 PM on Aug 8, 2023 |
The allotment process decides how many shares each investor will receive. Concord Biotech’s allotment details were closely scrutinized by investors, and it’s essential to understand how the shares were allocated.
Expert Opinions and Ratings
Financial analysts and experts play a vital role in providing insights and recommendations for IPO investors. These experts assess Concord Biotech’s potential for growth, profitability, and future prospects. Positive recommendations from reputable analysts can boost investor confidence.
Concord Biotech IPO Registrar
- Link Intime India Private Ltd
- Phone: +91-22-4918 6270
- Email: concordbiotech.ipo@linkintime.co.in
- Website: https://linkintime.co.in/mipo/ipoallotment.html
Concord Biotech IPO Lead Manager(s)
- 1. Kotak Mahindra Capital Company Limited (Past IPO Performance)
- 2. Citigroup Global Markets India Private Limited (Past IPO Performance)
- 3. Jefferies India Private Limited (Past IPO Performance)
Lead Manager Reports
- IPO Lead Manager Performance Summary
- IPO Lead Manager Performance Tracker
Company Contact Information
- Concord Biotech Limited
- 1482-86,Trasad Road Dholka,
- Ahmedabad – 382225
- Phone: 079-6813 8700
- Email: complianceofficer@concordbiotech.com
- Website: http://www.concordbiotech.com/
Concord Biotech’s decision to go public through an IPO was a significant move for the company’s growth and expansion. With a robust product portfolio, sound financials, and positive market reputation, they attracted the attention of potential investors. However, it’s essential for investors to conduct their due diligence and consider expert opinions before making investment decisions.
FAQ
1. What is Concord Biotech IPO?
Concord Biotech is all set to launch its main-board IPO, offering 20,925,652 equity shares with a face value of ₹1 each, amounting to a total of ₹[.] Crores. The issue price per share will range from [.] to [.].
The registrar for the IPO is Link Intime India Private Ltd, and the company’s shares are intended to be listed on both BSE and NSE stock exchanges.
2. When Concord Biotech will open?
Investors can participate in the IPO from August 4, 2023, until August 8, 2023.
3. What is Concord Biotech IPO size?
Concord Biotech IPO size Rs.[.]
4. How to apply Concord Biotech IPO from Zerodha?
Zerodha customers have the convenience of applying online for the Concord Biotech IPO using UPI as their preferred payment gateway. To do so, Zerodha clients can follow these simple steps:
- Visit the Zerodha website and log in to the Console.
- Navigate to the Portfolio section and click on the IPOs link.
- Locate the ‘Concord Biotech IPO’ row and click the ‘Bid’ button.
- Fill in the necessary details, including your UPI ID, desired Quantity of shares, and the Price.
- Once the information is entered, click ‘Submit’ to finalize the IPO application form.
- After completing the submission, visit your UPI App (either net banking or BHIM) to approve the mandate for the IPO transaction.
5. How has Concord Biotech’s financial performance been?
Concord Biotech has exhibited steady financial growth, indicating a strong financial position. Their financial reports showcase positive performance in the market.
6. How was the IPO price determined?
The IPO price is determined based on various factors, including the company’s valuation, prevailing market conditions, and investor demand. A well-calibrated IPO price can attract potential investors.
7. How were the shares allotted to investors?
The allotment process decides how many shares each investor will receive. The allotment details are closely scrutinized by investors, and the allocation is based on various factors.
